CN104540385B - 嘧啶基酪氨酸激酶抑制剂 - Google Patents

嘧啶基酪氨酸激酶抑制剂 Download PDF

Info

Publication number: CN104540385B
Authority: CN; China
Prior art keywords: compound; amino; chloro; oxo; bipiperidine
Prior art date: 2012-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN201380036869.5A

Other languages

English (en)

Chinese (zh)

Other versions

CN104540385A (zh

Inventor

B.T.霍普金斯

P.康伦

T.R.钱

T.J.詹金斯

X.蔡

M.休莫拉

X.施

R.A.米勒

A.汤普森

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biogen MA Inc

Viracta Therapeutics Inc

Original Assignee

Sunesis Pharmaceuticals Inc

Biogen Idec MA Inc

Biogen MA Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-08

Filing date

2013-06-07

Publication date

2018-06-05

2013-06-07 Application filed by Sunesis Pharmaceuticals Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Sunesis Pharmaceuticals Inc

2013-06-07 Priority to CN201810384098.3A priority Critical patent/CN109305959B/zh

2013-06-07 Priority to CN202110783143.4A priority patent/CN113549055A/zh

2015-04-22 Publication of CN104540385A publication Critical patent/CN104540385A/zh

2018-06-05 Application granted granted Critical

2018-06-05 Publication of CN104540385B publication Critical patent/CN104540385B/zh

Status Expired - Fee Related legal-status Critical Current

2033-06-07 Anticipated expiration legal-status Critical

Links

0 *c1cc(N)cc(Cl)c1 Chemical compound *c1cc(N)cc(Cl)c1 0.000 description 5
HSJRIBTUZWQGRM-UHFFFAOYSA-N CCCCC1(CNc2ncnc(N)c2F)CC1 Chemical compound CCCCC1(CNc2ncnc(N)c2F)CC1 HSJRIBTUZWQGRM-UHFFFAOYSA-N 0.000 description 1
IXLXXXLGJXSJBV-FGJGXXMFSA-N Cc1cc(N[C@H](CCCN2[C@@H](CN(CC3)c4ncnc(N)c4F)C3C(N)=O)C2=O)cc(Cl)c1 Chemical compound Cc1cc(N[C@H](CCCN2[C@@H](CN(CC3)c4ncnc(N)c4F)C3C(N)=O)C2=O)cc(Cl)c1 IXLXXXLGJXSJBV-FGJGXXMFSA-N 0.000 description 1
GSTXGJILPVWAEE-UHFFFAOYSA-N O=C1NCCCC11CC1 Chemical compound O=C1NCCCC11CC1 GSTXGJILPVWAEE-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

CN201380036869.5A 2012-06-08 2013-06-07 嘧啶基酪氨酸激酶抑制剂 Expired - Fee Related CN104540385B (zh)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
CN201810384098.3A CN109305959B (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂
CN202110783143.4A CN113549055A (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261657360P	2012-06-08	2012-06-08
US61/657,360		2012-06-08
PCT/US2013/044800 WO2013185084A1 (en)	2012-06-08	2013-06-07	Pyrimidinyl tyrosine kinase inhibitors

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201810384098.3A Division CN109305959B (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂
CN202110783143.4A Division CN113549055A (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂

Publications (2)

Publication Number	Publication Date
CN104540385A CN104540385A (zh)	2015-04-22
CN104540385B true CN104540385B (zh)	2018-06-05

Family

ID=49712704

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CN201380036869.5A Expired - Fee Related CN104540385B (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂
CN201810384098.3A Active CN109305959B (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂
CN202110783143.4A Pending CN113549055A (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CN201810384098.3A Active CN109305959B (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂
CN202110783143.4A Pending CN113549055A (zh)	2012-06-08	2013-06-07	嘧啶基酪氨酸激酶抑制剂

Country Status (30)

Country	Link
US (6)	US9394277B2 (2)
EP (3)	EP3753934A1 (2)
JP (6)	JP6214643B2 (2)
KR (4)	KR102102587B1 (2)
CN (3)	CN104540385B (2)
AR (1)	AR091273A1 (2)
AU (5)	AU2013271407B2 (2)
BR (2)	BR122021002178B1 (2)
CA (2)	CA3108186A1 (2)
CY (1)	CY1120638T1 (2)
DK (1)	DK2858499T3 (2)
EA (2)	EA027823B1 (2)
ES (2)	ES2684268T3 (2)
HR (1)	HRP20181294T1 (2)
HU (1)	HUE039897T2 (2)
IL (2)	IL235938B (2)
IN (1)	IN2014DN10576A (2)
LT (1)	LT2858499T (2)
MX (2)	MX363672B (2)
NZ (1)	NZ702715A (2)
PH (2)	PH12018501463B1 (2)
PL (1)	PL2858499T3 (2)
PT (1)	PT2858499T (2)
RS (1)	RS57978B1 (2)
SG (2)	SG11201408173WA (2)
SI (1)	SI2858499T1 (2)
SM (1)	SMT201800442T1 (2)
TW (3)	TWI592406B (2)
WO (1)	WO2013185084A1 (2)
ZA (1)	ZA201409255B (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2473049T (pt) *	2009-09-04	2019-03-04	Sunesis Pharmaceuticals Inc	Inibidores de tirosina quinase de bruton
US9273028B2 (en)	2010-10-29	2016-03-01	Biogen Ma Inc.	Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) *	2012-06-08	2016-05-31	Biogen Ma Inc.	Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) *	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
EP3080103B9 (en) *	2013-12-11	2018-09-19	Biogen MA Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015151006A1 (en)	2014-03-29	2015-10-08	Lupin Limited	Substituted purine compounds as btk inhibitors
WO2015170266A1 (en)	2014-05-07	2015-11-12	Lupin Limited	Substituted pyrimidine compounds as btk inhibitors
EA034931B1 (ru)	2014-10-24	2020-04-08	Бристол-Майерс Сквибб Компани	Индолкарбоксамидные соединения
JP7214632B2 (ja)	2016-07-21	2023-01-30	バイオジェンエムエーインク．	ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2019208805A1 (ja)	2018-04-27	2019-10-31	小野薬品工業株式会社	Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
US12109193B2 (en)	2018-07-31	2024-10-08	Loxo Oncology Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
US20220143049A1 (en)	2019-03-21	2022-05-12	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en)	2019-11-08	2022-09-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US20240100172A1 (en)	2020-12-21	2024-03-28	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
US20240216330A1 (en)	2021-04-02	2024-07-04	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
US20260083848A1 (en)	2021-11-03	2026-03-26	Viracta Therapeutics, Inc.	Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Vecabrutinib for the treatment of graft-versus-host disease
MX2024007328A (es)	2021-12-14	2024-09-30	Crossfire Oncology Holding B V	Inhibidores macrociclicos de btk.
WO2024246287A1 (en)	2023-06-02	2024-12-05	Crossfire Oncology Holding B.V.	Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024256568A1 (en)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Process for preparing macrocyclic btk inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050143372A1 (en) *	2001-10-30	2005-06-30	Shomir Ghosh	Compounds, pharmaceutical compositions and methods of use therefor
US20060189638A1 (en) *	2005-02-18	2006-08-24	Rawlins David B	4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
CN101610676A (zh) *	2006-09-22	2009-12-23	药品循环公司	布鲁顿酪氨酸激酶的抑制剂
CN101932573A (zh) *	2008-02-05	2010-12-29	霍夫曼-拉罗奇有限公司	新型吡啶酮类和哒嗪酮类
CN102159214A (zh) *	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20120004096A1 (en) *	2010-06-30	2012-01-05	Chevron U.S.A. Inc.	On-site drying of aqueous salt for ionic liquid make-up
US20120058996A1 (en) *	2008-12-19	2012-03-08	Bristol-Myers Squibb Company	Carbazole carboxamide compounds useful as kinase inhibitors

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1624A (en) *		1840-06-10		Cooking-stove
US4528138A (en)	1984-06-20	1985-07-09	E. R. Squibb & Sons, Inc.	16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en)	1986-07-30	1990-03-27	Alcon Laboratories, Inc.	Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr)	1985-10-03	1988-12-02	Merck Sharp & Dohme	Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de)	1991-01-15	1996-09-15	Alcon Lab Inc	Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en)	1991-03-27	1993-05-18	Alcon Laboratories, Inc.	Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en)	2000-11-21	2005-07-19	Sunesis Pharmaceuticals, Inc.	Extended tethering approach for rapid identification of ligands
JP2003528072A (ja)	2000-03-17	2003-09-24	ブリストル−マイヤーズスクイブファーマカンパニー	マトリックスメタロプロテアーゼおよびＴＮＦ−αの阻害剤としての環状β−アミノ酸誘導体
MY137020A (en)	2000-04-27	2008-12-31	Abbott Lab	Diazabicyclic central nervous system active agents
IL152771A0 (en)	2000-06-26	2003-06-24	Pfizer Prod Inc	PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
PE20020507A1 (es) *	2000-10-17	2002-06-25	Schering Corp	Compuestos no-imidazoles como antagonistas del receptor histamina h3
EP1442039A1 (en)	2001-10-31	2004-08-04	Bayer HealthCare AG	Pyrimido (4,5-b) indole derivatives
MXPA05007485A (es)	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AU2004282179B2 (en)	2003-10-14	2011-05-19	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein kinase inhibitors
US20080253960A1 (en) *	2004-04-01	2008-10-16	The Trustees Of The University Of Pennsylvania Center For Technology Transfer	Lipoprotein-Based Nanoplatforms
WO2005117909A2 (en)	2004-04-23	2005-12-15	Exelixis, Inc.	Kinase modulators and methods of use
FR2870541B1 (fr)	2004-05-18	2006-07-14	Proskelia Sas	Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es)	2004-09-09	2006-11-29	Sanofi Aventis	Derivados de 2- morfolino-4-pirimidona
ATE482213T1 (de) *	2004-11-04	2010-10-15	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
CN101115726A (zh)	2004-12-03	2008-01-30	先灵公司	作为cb1拮抗剂的取代哌嗪
CA2590961C (en)	2004-12-28	2013-11-26	Exelixis, Inc.	[1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7880002B2 (en)	2004-12-29	2011-02-01	Millennium Pharmaceuticals, Inc.	Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US20060281700A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en)	2005-06-10	2006-12-14	Gaul Michael D	Aminopyrimidines as kinase modulators
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
CN103626742B (zh)	2005-11-01	2017-04-26	塔格根公司	激酶的联-芳基间-嘧啶抑制剂
US20070142369A1 (en) *	2005-12-21	2007-06-21	Margaret Van Heek	Combination of an H3 antagonist/inverse agonist and an appetite suppressant
WO2008005368A2 (en)	2006-06-30	2008-01-10	Abbott Laboratories	Piperazines as p2x7 antagonists
WO2008014307A2 (en)	2006-07-26	2008-01-31	Novartis Ag	Inhibitors of undecaprenyl pyrophosphate synthase
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
WO2008033858A2 (en) *	2006-09-11	2008-03-20	Cgi Pharmaceuticals, Inc.	Kinase inhibitors, and methods of using and identifying kinase inhibitors
AR065494A1 (es) *	2007-03-02	2009-06-10	Schering Corp	Derivados de piperidina y metodos de uso de los mismos
EP2125819B1 (en)	2007-03-21	2014-10-22	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
US20100216779A1 (en)	2007-06-01	2010-08-26	Glaxosmithkline Llc	Imidazopyridine Kinase Inhibitors
EP2283358B1 (en)	2008-04-29	2015-04-22	Immunexcite, Inc.	Immunomodulating compositions and methods of use thereof
WO2010068788A1 (en) *	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Heterocyclic amides as btk inhibitors
EP2379559B1 (en) *	2009-01-06	2017-10-25	Dana-Farber Cancer Institute, Inc.	Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2435442B1 (de)	2009-05-25	2016-01-13	Sandoz AG	Verfahren zur herstellung von ceftobiprol medocaril
US9029359B2 (en)	2009-09-04	2015-05-12	Biogen Idec Ma, Inc.	Heteroaryl Btk inhibitors
PT2473049T (pt)	2009-09-04	2019-03-04	Sunesis Pharmaceuticals Inc	Inibidores de tirosina quinase de bruton
US9273028B2 (en)	2010-10-29	2016-03-01	Biogen Ma Inc.	Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en)	2012-06-08	2016-05-31	Biogen Ma Inc.	Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es)	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
US10280169B2 (en)	2013-12-11	2019-05-07	Biogen Ma Inc.	Biaryl bruton's tyrosine kinase inhibitors
EP3080103B9 (en)	2013-12-11	2018-09-19	Biogen MA Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20170298446A1 (en)	2014-10-03	2017-10-19	Ohio State Innovation Foundation	Biomarkers of bruton tyrosine kinase inhibitor resistance
JP7214632B2 (ja) *	2016-07-21	2023-01-30	バイオジェンエムエーインク．	ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物

2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 PH PH1/2018/501463A patent/PH12018501463B1/en unknown
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh not_active Expired - Fee Related
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja not_active Expired - Fee Related
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko not_active Expired - Fee Related
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh not_active IP Right Cessation
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active Active
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 MX MX2019003618A patent/MX385593B/es unknown
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko not_active Ceased
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en not_active Ceased
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en not_active Withdrawn
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh not_active IP Right Cessation
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Ceased
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en not_active Ceased
- 2013-06-07 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh not_active IP Right Cessation
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en not_active IP Right Cessation
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en not_active Not-in-force
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt not_active IP Right Cessation
- 2013-06-08 SM SM20180442T patent/SMT201800442T1/it unknown
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699B1/en unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en not_active Ceased
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en not_active Ceased
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
2021
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en not_active Abandoned
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en not_active Abandoned
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending
2024
- 2024-08-23 US US18/813,750 patent/US20240417389A1/en active Pending

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050143372A1 (en) *	2001-10-30	2005-06-30	Shomir Ghosh	Compounds, pharmaceutical compositions and methods of use therefor
US20060189638A1 (en) *	2005-02-18	2006-08-24	Rawlins David B	4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
CN101610676A (zh) *	2006-09-22	2009-12-23	药品循环公司	布鲁顿酪氨酸激酶的抑制剂
CN101932573A (zh) *	2008-02-05	2010-12-29	霍夫曼-拉罗奇有限公司	新型吡啶酮类和哒嗪酮类
CN102159214A (zh) *	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20120058996A1 (en) *	2008-12-19	2012-03-08	Bristol-Myers Squibb Company	Carbazole carboxamide compounds useful as kinase inhibitors
US20120004096A1 (en) *	2010-06-30	2012-01-05	Chevron U.S.A. Inc.	On-site drying of aqueous salt for ionic liquid make-up

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"The Akp-Btk value method and the resultsfor the retrieval of the parameters of the Earth"s free core nutation ";雷湘鄂等;《Acta Seismologica Sinica》;20000515;第13卷(第3期);342-350 *
"酪氨酸激酶Btk家族的结构和功能";苏珊等;《医学分子生物学杂志》;20060615;第3卷(第6期);442-445 *

Also Published As

Publication number	Publication date
CA2875799C (en)	2021-03-23
BR112014030655B1 (pt)	2021-04-20
ES2684268T3 (es)	2018-10-02
IN2014DN10576A (2)	2015-08-28
TWI719209B (zh)	2021-02-21
KR102102587B1 (ko)	2020-04-22
JP2015518903A (ja)	2015-07-06
EP3385263B1 (en)	2020-07-22
AU2019203476A1 (en)	2019-06-06
EP3753934A1 (en)	2020-12-23
DK2858499T3 (en)	2018-08-20
PH12014502699A1 (en)	2015-02-02
TWI792158B (zh)	2023-02-11
SMT201800442T1 (it)	2018-09-13
TW202142535A (zh)	2021-11-16
IL235938B (en)	2020-10-29
JP2019077728A (ja)	2019-05-23
JP2021073299A (ja)	2021-05-13
BR112014030655A2 (pt)	2017-06-27
MX2014015044A (es)	2015-09-22
KR102468430B1 (ko)	2022-11-21
CN109305959B (zh)	2022-02-08
JP2017193583A (ja)	2017-10-26
US20230174511A1 (en)	2023-06-08
HK1209284A1 (en)	2016-04-01
AU2017201536B2 (en)	2019-03-07
AR091273A1 (es)	2015-01-21
BR122021002178B1 (pt)	2022-03-22
CA3108186A1 (en)	2013-12-12
CN109305959A (zh)	2019-02-05
MX2019003618A (es)	2019-07-18
AU2017201536A1 (en)	2017-03-23
US20240417389A1 (en)	2024-12-19
LT2858499T (lt)	2018-09-10
JP2023052415A (ja)	2023-04-11
US20160304494A1 (en)	2016-10-20
EP2858499B1 (en)	2018-05-16
IL277951A (en)	2020-11-30
EP3385263A1 (en)	2018-10-10
MX385593B (es)	2025-03-18
US10618887B2 (en)	2020-04-14
PL2858499T3 (pl)	2019-03-29
PT2858499T (pt)	2018-10-24
KR20200043497A (ko)	2020-04-27
TWI592406B (zh)	2017-07-21
RS57978B1 (sr)	2019-01-31
CN104540385A (zh)	2015-04-22
SG11201408173WA (en)	2015-01-29
MX363672B (es)	2019-03-29
KR20210072139A (ko)	2021-06-16
EA201790418A1 (ru)	2017-11-30
US20210017155A1 (en)	2021-01-21
US20190047986A1 (en)	2019-02-14
AU2021202412A1 (en)	2021-05-20
US20150158843A1 (en)	2015-06-11
TW201805279A (zh)	2018-02-16
WO2013185084A1 (en)	2013-12-12
AU2013271407A1 (en)	2015-01-22
EA201492056A1 (ru)	2015-05-29
BR112014030655A8 (pt)	2018-01-02
HRP20181294T1 (hr)	2018-10-05
ZA201409255B (en)	2015-12-23
KR20150036020A (ko)	2015-04-07
AU2013271407B2 (en)	2016-12-08
CN113549055A (zh)	2021-10-26
AU2022275504A1 (en)	2023-01-05
ES2834333T3 (es)	2021-06-17
CY1120638T1 (el)	2019-12-11
HUE039897T2 (hu)	2019-02-28
SI2858499T1 (sl)	2018-10-30
KR20220154850A (ko)	2022-11-22
US9944622B2 (en)	2018-04-17
EA027823B1 (ru)	2017-09-29
JP6214643B2 (ja)	2017-10-18
PH12018501463A1 (en)	2019-03-04
JP2021073298A (ja)	2021-05-13
SG10201708535UA (en)	2017-11-29
IL235938A0 (en)	2015-02-01
EP2858499A1 (en)	2015-04-15
TW201410668A (zh)	2014-03-16
CA2875799A1 (en)	2013-12-12
PH12018501463B1 (en)	2024-03-27
AU2019203476B2 (en)	2021-01-28
NZ702715A (en)	2016-11-25
US9394277B2 (en)	2016-07-19
PH12014502699B1 (en)	2015-02-02
EP2858499A4 (en)	2016-01-20

Legal Events

Date	Code	Title	Description
2015-04-22	C06	Publication
2015-04-22	PB01	Publication
2015-06-17	C53	Correction of patent of invention or patent application
2015-06-17	CB02	Change of applicant information	Address after: Massachusetts, USA Applicant after: BIOGEN MA Inc. Applicant after: SUNESIS PHARMACEUTICALS, Inc. Address before: Massachusetts, USA Applicant before: Biogen Idec MA Inc. Applicant before: SUNESIS PHARMACEUTICALS, Inc.
2015-06-17	COR	Change of bibliographic data	Free format text: CORRECT: ADDRESS; FROM: Free format text: CORRECT: APPLICANT; FROM: BIOGEN IDEC MA TO: BIOGEN MA INC.
2015-07-01	C10	Entry into substantive examination
2015-07-01	SE01	Entry into force of request for substantive examination
2016-04-01	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1209284 Country of ref document: HK
2018-06-05	GR01	Patent grant
2018-06-05	GR01	Patent grant
2025-05-30	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20180605
2025-05-30	CF01	Termination of patent right due to non-payment of annual fee

Publication	Publication Date	Title
CN104540385B (zh)	2018-06-05	嘧啶基酪氨酸激酶抑制剂
HK40043767A (en)	2021-09-24	Pyrimidinyl derivatives useful as tyrosine kinase inhibitors
HK1209284B (zh)	2019-09-06	嘧啶基酪氨酸激酶抑制劑
HK1262106A1 (en)	2020-01-10	Pyrimidinyl tyrosine kinase inhibitors
HK1262106B (en)	2021-04-16	Pyrimidinyl tyrosine kinase inhibitors